MiraKind Research Registry for PROSTOX

PROSTOX through the MiraKind Research Registry

You are eligible to obtain PROSTOX testing through the MiraKind Research Registry if you:

  • Have a localized prostate cancer diagnosis
  • Have not received radiation therapy to the prostate
  • Agree to participate in the MiraKind Research Registry, which entails responding to periodic questionnaires.
  • Are unable to have a physician order PROSTOX directly at this time or live outside of the US

Also, you must be considering one or both of these types of radiation therapy to the prostate:

  • SBRT, 5-7 sessions over 10 days
  • CFRT, 35-45 sessions over 8-10 weeks

$500* each
or $900* for both tests

Start Now

*This discounted cost for PROSTOX is only available through the MiraKind Research Registry. 20% of your purchase supports MiraKind.

Questions? Read FAQ or Contact us

Frequently asked questions about PROSTOX testing through the MiraKind Research Registry

Accessing PROSTOX
Taking the test
Participating in our research registry

Disclosure: Any discussion of medical management options is for general informational purposes only and does not constitute a medical recommendation. All medical management decisions should be made based on consultation between each patient and his or her healthcare professional.

References

  1. Kishan AU, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Network Open 2019;2:e188006.
  2. Weidhaas, JB, et al. MicroRNA-based biomarkers of the radiation response in prostate cancer. Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020) 163-163. DOI: 10.1200/JCO.2020.38.6_suppl.163.
  3. Kishan AU, et al. Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. Journal for Radiotherapy and Oncology 2022;167:226-232. doi: 10.1016/j.radonc.2021.12.040.
  4. Kishan AU, Marco N, Ma TM, Steinberg ML, Sachdeva A, Cao M, Ballas LK, Rietdorf E, Telesca D, Weidhaas JB. Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial. Clin Transl Radiat Oncol. 2023 Feb 8;39:100594. doi: 10.1016/j.ctro.2023.100594. PMID: 36880064; PMCID: PMC9984404.
  5. Kishan AU, et al. Validation and Derivation of miRNA-Based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer. Clin Cancer Res 15 June 2025; 31 (12): 2530–2538.

about MiraKind

education

testing information

research

our research

studies

hormones, the KRAS-variant and breast cancer risk study

publications

get involved

subscribe to our newsletter

Subscribe Now

socials

Disclaimer

Any discussion of medical management options on this website is for general informational purposes only and does not constitute a medical recommendation. All medical management decisions should be made based on consultation between each patient and his or her healthcare professional.

arrow up to top